Novo Nordisk Diabetes Treatment
-
{
- All
- News
-
Novo Responds To GLP-1 Drug Ozempic Causing Vision Loss Claims: What Semaglutide Data Shows
Novo Nordisk says a large pooled analysis of clinical trials found no increased risk of rare NAION with semaglutide. Here is what the new evidence means for diabetes patients in India amid concerns over sudden vision loss.
-
Can A Bunch Of Doctors Keep An $8 Billion Secret? Not On Twitter
In New Orleans Monday, a major medical organization attempted a feat perhaps as hard as treating the disease doctors were there to discuss. They asked a packed convention hall of attendees not to tweet the confidential, market-moving data they had flown in to see.
-
Novo Responds To GLP-1 Drug Ozempic Causing Vision Loss Claims: What Semaglutide Data Shows
Novo Nordisk says a large pooled analysis of clinical trials found no increased risk of rare NAION with semaglutide. Here is what the new evidence means for diabetes patients in India amid concerns over sudden vision loss.
-
Can A Bunch Of Doctors Keep An $8 Billion Secret? Not On Twitter
In New Orleans Monday, a major medical organization attempted a feat perhaps as hard as treating the disease doctors were there to discuss. They asked a packed convention hall of attendees not to tweet the confidential, market-moving data they had flown in to see.
